Evidence map›Paper›PMID 40495990›Full record

ArticleFrontiers in cardiovascular medicine2025

Effectiveness and safety of rivaroxaban in patients with atrial fibrillation and heart failure in clinical practice: an indirect comparison of national and international registries.

Jose Maria Cepeda, Nicolas Manito, Alejandro Recio Mayoral, Iñaki Lekuona, Miguel Castillo Orive, Elvira Blanco Labrador, María Teresa Blasco, Nuria Farré, José Manuel García Pinilla, Javier Jiménez-Candil and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jose Maria CepedaInternal Medicine Department, Hospital Vega Baja, Orihuela, Spain.
Nicolas ManitoCardiology Department, Hospital Universitario de Bellvitge, Barcelona, Spain.
Alejandro Recio MayoralCardiology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Iñaki LekuonaCardiology Department, Hospital Galdakao-Usansolo, Bizkaia, Spain.
Miguel Castillo OriveCardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Elvira Blanco LabradorCardiology Department, Complexo Hospitalario de Ourense, Ourense, Spain.
María Teresa BlascoCardiology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Nuria FarréCardiology Department, Hospital del Mar, Barcelona, Spain.
José Manuel García PinillaCardiology Department, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
Javier Jiménez-CandilCardiology Department, Hospital Universitario de Salamanca, Insitituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca, CIBER-CV, Salamanca, Spain.
Carles RafolsMedical Department, Bayer Hispania, Barcelona, Spain.
Juan Jose Gomez DoblasCardiology Department, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The objective of the study was to analyze and compare the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF) and heart failure (HF). Methods: The clinical profile and outcomes of the FARAONIC study were indirectly compared with those of the ROCKET-AF trial and other national and international observational registries. Results: In FARAONIC, the median age was 73.7 years, 34.1% were women, and the median CHA Conclusion: In clinical practice, AF patients with HF, anticoagulated with rivaroxaban are old, have many comorbidities and have a high thromboembolic risk. Despite this, rates of adverse events are low.

Indexed as

anticoagulationatrial fibrillationclinical practiceheart failurerivaroxaban

Identifiers

PMID40495990
PMCPMC12150239

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.